Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis

This article was originally published in The Pink Sheet Daily

Executive Summary

UCSF researcher Alan Verkman will have an ongoing role in lead optimization and development, BioMarin’s CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease

10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.

Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease

10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.

BioMarin Submits Kuvan For Phenylketonuria

Firm is asking FDA for a priority review, which would potentially allow for a late 2007 launch of the orphan drug.

Related Content

Topics

UsernamePublicRestriction

Register

PS066497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel